COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy of Metformin in Preventing Diabetes in China (ChinaDPP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03441750
Recruitment Status : Active, not recruiting
First Posted : February 22, 2018
Last Update Posted : July 1, 2019
Information provided by (Responsible Party):
Chinese Association of Geriatric Research

Brief Summary:
A multicentred, randomized, open study to evaluate the efficacy of metformin in preventing Diabetes.

Condition or disease Intervention/treatment Phase
PreDiabetes Drug: metformin Other: Standard lifestyle intervention Phase 4

Detailed Description:
The increasing prevalence of prediabetes had been documented in the recent national surveillance in China. Prediabetes is an important risk factor for developing overt Diabetes and macro/micro vascular diseases. Pharmaceutical medications such as metformin had been proved effective in preventing Diabetes. Local studies are in need to guide the clinicians in their daily practice to prevent Diabetes in China. Therefore, China Diabetes Prevention Program(China DPP)is designed and conducted to compare the efficacy of metformin combined with lifestyle intervention versus lifestyle intervention alone in preventing Diabetes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1724 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Multicentre, Open-labelled, Randomized, Controlled Study to Evaluate the Efficacy of Metformin in Preventing Diabetes in China.
Actual Study Start Date : April 25, 2017
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: metformin plus standard lifestyle intervention
Metformin starting dose is 850mg/d, it will be titrated to 850mg twice daily after 2 weeks and maintained until the last subject completes 2 years' intervention.
Drug: metformin
Metformin tablets will be administrated in the experimental arm.
Other Name: Glucophage immediate release formulation

Standard lifestyle intervention
Standard lifestyle advice will be united for all subjects by providing special booklet.
Other: Standard lifestyle intervention

Standard lifestyle advice will be united for all subjects by providing special booklet.

  • All participants will receive 20-30 minutes individual or group session with assigned nurse addressing the harm of prediabetes and the importance of a healthy lifestyle for preventing Diabetes.
  • The amount of energy intake of the participants will be calculated based on the ideal body weight and physical activity levels. The sample recipe will be explained by the nurse and provided in the diet instruction.
  • Moderate intensity physical activity (150 minutes per week) is recommended.
  • Smoking cessation is encouraged for the smoker.
  • Excessive alcohol intake is encouraged to avoid.

Primary Outcome Measures :
  1. Rate of newly diagnosed diabetes [ Time Frame: The primary outcome will be evaluated when the last subject completes 2 years' intervention. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  1. Diagnosis of IGR before the randomization based on the 1999 WHO diagnostic and classification criteria.
  2. Age: 18 ≤age≤70 years old.
  3. Not on a treatment of anti-diabetic agents, including Chinese traditional herbs lowering blood glucose for at least 6 months before screening.
  4. Male or non-pregnant, non-breastfeeding females, females without birthing plan in next three years.
  5. Body mass index (BMI) :21 kg/m2 ≤BMI<32 kg/m2.
  6. Written informed consent given before any trial-related activities are carried out.

Main exclusion Criteria:

  1. Administration with medications for pre-existed diseases affect glucose metabolism (except thiazide diuretics when its daily dose≤12.5mg).
  2. Administration with anti-obesity agents (including Chinese traditional medicine) within 6 months of enrolment and during intervention.
  3. Administration with three or more than three types antihypertensive drugs.
  4. Diabetes patients (subjects with prior history of gestational Diabetes will not be excluded).
  5. Have any of the following cardiovascular conditions within 3 months prior to the screening visit: acute myocardial infarction, congestive heart failure defined as New York Heart Association class III/IV or left ventricular ejection fraction ≤40%,) or cerebrovascular accident.
  6. Persistent uncontrolled hypertension (systolic blood pressure ≥160mmHg, or diastolic blood pressure ≥100 mmHg).
  7. Impaired liver function, have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, ALT or AST levels ≥3 times the upper limit of the reference range at the screening visit.
  8. Renal dysfunction (eGFR<45ml/min).
  9. Patients ventilated by ventilator.
  10. Hypersensitivity to metformin or to any of the excipients such as povidone K 30, magnesium stearate and hypromellose.
  11. Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic respiratory disease).
  12. Acute alcohol intoxication, alcoholism.
  13. Severe chronic gastrointestinal disease.
  14. Severe psychiatric illness.
  15. Cancer requiring treatment in past 5 years.
  16. Uncontrolled thyroid diseases.
  17. Women who are pregnant or breastfeeding .
  18. Participation in another clinical trial within the past 30 days .
  19. Other significant disease that in the Investigator's opinion would exclude the subject from the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03441750

Layout table for location information
China, Beijing
Fuwai hospital
Beijing, Beijing, China, 100037
Sponsors and Collaborators
Chinese Association of Geriatric Research
Layout table for investigator information
Principal Investigator: Guangwei Li, M.D., Ph.D. Fuwai Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Chinese Association of Geriatric Research Identifier: NCT03441750    
Other Study ID Numbers: ChineseAGR
First Posted: February 22, 2018    Key Record Dates
Last Update Posted: July 1, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prediabetic State
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs